TOKYO – Astellas Pharma Inc. is streamlining its product lineup by selling off rights to 16 of its long-listed products to LTL Pharma Co. Ltd. in a deal worth ¥20.1 billion (US$177 million), a move that will enable Astellas to focus on newer and more profitable drugs.